Comments on Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> 2019, <i>11</i>, 491

Comments on Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> 2019, <i>11</i>, 491

In contrast to the prevailing arguments presented in the current review, the incidence of neutralising antibody (NAb) formation is not a significant issue for any of the present type A therapeutic botulinum neurotoxin (BoNT) products. Furthermore, clinical non-responsiveness is poorly correlated wit...

Full description

Bibliographic Details
Main Authors: Keith Foster, Matthew Beard
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Toxins
Subjects:
abobotulinumtoxin a
botulinum neurotoxin (bont)
immunogenicity
incobotulinumtoxin a
neutralising antibody (nab)
onabotulinumtoxin a
secondary non-responsiveness (snr)
Online Access:https://www.mdpi.com/2072-6651/12/2/71

Internet

https://www.mdpi.com/2072-6651/12/2/71

Similar Items